^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    1d
    Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children (clinicaltrials.gov)
    P4, N=431, Completed, Laval University | Recruiting --> Completed | Phase classification: P3 --> P4
    Trial completion • Phase classification
    1d
    A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) (clinicaltrials.gov)
    P1, N=65, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    1d
    Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults (clinicaltrials.gov)
    P1, N=27, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed
    Trial completion
    1d
    Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Cancer Vaccines Limited | Trial completion date: Feb 2026 --> Jul 2027 | Trial primary completion date: May 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    1d
    Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (clinicaltrials.gov)
    P1/2, N=750, Active, not recruiting, Sanofi Pasteur, a Sanofi Company | Recruiting --> Active, not recruiting
    Enrollment closed
    1d
    Application of mRNA Immunotherapy Technology in EB Virus Related Diseases (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Xinqiao Hospital of Chongqing
    New P1 trial
    1d
    Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons (clinicaltrials.gov)
    P4, N=250, Recruiting, University Ghent | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    5d
    A Study of TIL in Advanced Solid Tumors (CZ) (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Shanghai Juncell Therapeutics | Initiation date: Dec 2025 --> May 2026
    Trial initiation date
    |
    cyclophosphamide • GC101 TIL
    5d
    Booster Dose of sIPV Co-administered With MMR and HepA-I. (clinicaltrials.gov)
    P4, N=889, Completed, Sinovac Biotech Co., Ltd | Not yet recruiting --> Completed | Trial completion date: Mar 2025 --> Oct 2025 | Trial primary completion date: Feb 2025 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    5d
    Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above (clinicaltrials.gov)
    P1, N=234, Completed, National Vaccine and Serum Institute, China | Active, not recruiting --> Completed
    Trial completion
    5d
    MATVAC-1: Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, Centre Hospitalier Universitaire de Besancon
    New P2 trial
    |
    Keytruda (pembrolizumab) • temozolomide • UCPVax
    5d
    Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial (clinicaltrials.gov)
    P1/2, N=744, Active, not recruiting, Sinovac Biotech Co., Ltd | Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date